PaxVax Announces New Commercial Senior Leadership

February 03, 2014 PaxVax Inc., a speciality vaccine company focused on travellers and biodefense markets with a social mission to ensure global access to its vaccines, today announced the expansion of its commercial leadership team, including appointments of: Linda Rubinstein as Chief Financial Officer; Piers Whitehead as Chief Corporate Development Officer; and Thomas Yonker as Vice President of Project Management. …

Anthrax vaccine showdown as PharmAthene’s SparVax Phase II gets FDA go ahead

PharmAthene have announced that the FDA has lifted the clinical hold previously placed on the Phase II study of it's next generation anthrax vaccine, SparVax. The FDA had originally placed a hold on the trial back in August 2012, requesting that PharmaAthene "provide additional stability data for both its engineering and GMP lots of U.S. manufactured Final Drug Product, as …

Enhancing existing vaccines, developing technologies for biodefense vaccines

Biodefense is traditionally a term associated with defensive measures taken against biological attack. Dr Michael Kurilla, Director, Office of BioDefense Research Affairs & Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS, spoke at the World Vaccine Congress 2012 in Washington on the application of biodefense to existing vaccines to prevent the potential impact from future pandemics. The necessity …